Lenocta (sodium stibogluconate) / VioQuest 
Welcome,         Profile    Billing    Logout  
 24 Diseases   4 Trials   4 Trials   245 News 


«123
  • ||||||||||  Lenocta (sodium stibogluconate) / VioQuest
    Clinical, Journal:  A Clinicoepidemiological Study of Pediatric Cutaneous Leishmaniasis in Sinjar Province, Iraq. (Pubmed Central) -  Mar 19, 2020   
    All patients were treated with intralesional injections of sodium stibogluconate and followed up for 3 months after the completion of treatment...A significant association was found between the number of lesions and the number of doses. Further studies are required to assess the treatment outcome indicators, including the genotype of leishmania.
  • ||||||||||  Lenocta (sodium stibogluconate) / VioQuest
    Journal:  Molecular Characterization of Aquaglyceroporine: A Novel Mutation in LmAQP1 from Leishmania major (MRHO/IR/75/ER). (Pubmed Central) -  Nov 3, 2019   
    The first line treatment for cutaneous leishmaniasis is pentavalent antimony such as sodium stibogluconate (pentostam) and meglumine antimonite (glucantime)...Based on from LmAQP1 role, it seems to be an appropriate candidate for drug development. According to search through internet, this is the first report of LmAQP1 from L. major (MRHO/IR/75/ER).
  • ||||||||||  Lenocta (sodium stibogluconate) / VioQuest
    Clinical, Journal:  Case Report: Mucosal Leishmaniasis Presenting with Nasal Septum Perforation after Almost Thirty Years. (Pubmed Central) -  Sep 11, 2019   
    ...The patient underwent 28 days of treatment with IV sodium stibogluconate and her symptoms improved significantly...Although ML is known to take years to decades to develop, there are few reported cases in the literature of such a long latency period. This report highlights the importance of considering ML in the differential diagnosis of chronic epistaxis in countries where leishmaniasis is endemic or in immigrants from these countries, even when presentation occurs decades after leaving an endemic region.
  • ||||||||||  Lenocta (sodium stibogluconate) / VioQuest
    Journal:  Andrographolide engineered gold nanoparticle to overcome drug resistant visceral leishmaniasis. (Pubmed Central) -  Aug 23, 2019   
    ...AGAunp exhibited strong antileishmanicidal effect both against wild type (IC 19 ± 1.7 µM) and sodium stibogluconate (IC 55 ± 7.3 µM)/paromomycin (IC 41 ± 6 µM) resistant strains...AGAunp macrophage cytotoxicity was significantly lower as compared to Amphotericin-B. Low toxic Andrographolide engineered gold nanoparticle emerged as promising alternatives in the control of wild and drug resistant VL.
  • ||||||||||  Lenocta (sodium stibogluconate) / VioQuest
    Journal:  Microwave-assisted synthesis of novel 5-substituted benzylidene amino-2-butyl benzofuran-3-yl-4-methoxyphenyl methanones as antileishmanial and antioxidant agents. (Pubmed Central) -  May 31, 2019   
    ...Compounds 4f (IC = 52.0 ± 0.09 µg/ml), 4h (IC = 56.0 ± 0.71 µg/ml) and 4l (IC = 59.3 ± 0.55 µg/ml) were shown significant antileishmanial when compared with standard sodium stibogluconate (IC = 490.0 ± 1.5 µg/ml)...Molecular docking study was carried out which replicating results of biological activity in case of initial hits 4f and 4h suggesting that these compounds have a potential to become lead molecules in drug discovery process. In silico ADME study was performed for predicting pharmacokinetic profile of the synthesised antileishmanial agents and expressed good oral drug like behaviour.
  • ||||||||||  Lenocta (sodium stibogluconate) / VioQuest, pentamidine oral (VLX103) / Verlyx
    Journal:  Do bismuth complexes hold promise as antileishmanial drugs? (Pubmed Central) -  May 22, 2019   
    Even after 70 years, pentavalent antimonials sodium stibogluconate and meglumine antimoniate remain the most important and cost-effective antileishmanial drugs...The main alternatives, amphotericin B, pentamidine and miltefosine, are expensive and not without their own problems...This review describes recent efforts into developing antileishmanial Bi(III) and Bi(V) drugs, which may resemble Sb analogs in effect and mode-of-action while providing lower mammalian cell toxicity and opportunities of oral delivery. Within the last 10 years, various studies concerning bismuth-based compounds as potential antileishmanial agents have been published. This review seeks to summarize the relevant studies and draw a conclusion as to whether bismuth complexes have the potential to be effective drugs.
  • ||||||||||  Lenocta (sodium stibogluconate) / VioQuest
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Head-to-Head:  Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa (clinicaltrials.gov) -  Mar 6, 2018   
    P3,  N=576, Recruiting, 
    This study showed that intralesional SSG has the best response against CL, while intralesional metronidazole was an effective alternative treatment. Not yet recruiting --> Recruiting | Trial completion date: Aug 2019 --> Nov 2019 | Initiation date: Dec 2017 --> Jan 2018 | Trial primary completion date: Aug 2019 --> Nov 2019
  • ||||||||||  Lenocta (sodium stibogluconate) / VioQuest
    Trial primary completion date:  Use of Sodium Stibogluconate as a Treatment for Leishmaniasis (clinicaltrials.gov) -  Feb 27, 2018   
    P1/2,  N=77, Completed, 
    Not yet recruiting --> Recruiting | Trial completion date: Aug 2019 --> Nov 2019 | Initiation date: Dec 2017 --> Jan 2018 | Trial primary completion date: Aug 2019 --> Nov 2019 Trial primary completion date: Apr 2016 --> Apr 2010
  • ||||||||||  Lenocta (sodium stibogluconate) / VioQuest
    Trial completion, Enrollment change, Trial primary completion date:  Use of Sodium Stibogluconate as a Treatment for Leishmaniasis (clinicaltrials.gov) -  May 5, 2017   
    P1/2,  N=77, Completed, 
    Initiation date: Aug 2017 --> Dec 2017 Enrolling by invitation --> Completed | N=1000 --> 77 | Trial primary completion date: Dec 2016 --> Apr 2016
  • ||||||||||  Lenocta (sodium stibogluconate) / VioQuest
    Trial primary completion date:  Use of Sodium Stibogluconate as a Treatment for Leishmaniasis (clinicaltrials.gov) -  Oct 25, 2016   
    P1/2,  N=1000, Enrolling by invitation, 
    Enrolling by invitation --> Completed | N=1000 --> 77 | Trial primary completion date: Dec 2016 --> Apr 2016 Trial primary completion date: Sep 2016 --> Dec 2016
  • ||||||||||  Lenocta (sodium stibogluconate) / VioQuest
    Trial primary completion date:  Use of Sodium Stibogluconate as a Treatment for Leishmaniasis (clinicaltrials.gov) -  Nov 1, 2015   
    P1/2,  N=1000, Enrolling by invitation, 
    N=24 --> 18 | Active, not recruiting --> Terminated Trial primary completion date: Sep 2015 --> Sep 2016
  • ||||||||||  Lenocta (sodium stibogluconate) / VioQuest
    Phase classification, Trial primary completion date:  Use of Sodium Stibogluconate as a Treatment for Leishmaniasis (clinicaltrials.gov) -  Apr 21, 2015   
    P1/2,  N=1000, Enrolling by invitation, 
    Trial primary completion date: Sep 2015 --> Sep 2016 Phase classification: P2 --> P1/2 | Trial primary completion date: Oct 2014 --> Sep 2015
  • ||||||||||  Lenocta (sodium stibogluconate) / VioQuest
    Trial termination:  Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome (clinicaltrials.gov) -  Aug 28, 2013   
    P1/2,  N=1, Terminated, 
    Recruiting --> Completed Active, not recruiting --> Terminated; Lack of funding, never moved into the phase II portion that was originally planned.
  • ||||||||||  Lenocta (sodium stibogluconate) / VioQuest
    Enrollment change:  Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome (clinicaltrials.gov) -  Aug 28, 2013   
    P1/2,  N=1, Terminated, 
    Active, not recruiting --> Terminated; Lack of funding, never moved into the phase II portion that was originally planned. N=20 --> 1